Syndesi Therapeutics SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Syndesi Therapeutics SA
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
The Dublin-based venture capital group will be looking to replicate the success of portfolio companies Inflazome and KaNDy, recently acquired by Roche and Bayer respectively, with the biotechs backed from its latest fund.
- Other Names / Subsidiaries
- AbbVie Inc.